American Society of Clinical Oncology (ASCO)

2026 Annual Meeting

WashU Medicine Presentations Follow Our X Updates Follow Our Bluesky Updates
20240227 Denardo 0459

WashU Medicine faculty members affiliated with Siteman Cancer Center will present their research at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2 in Chicago. See the button above for details.

Programming is subject to change. For the most current information, visit the conference program. And be sure to follow Siteman Cancer Center at #ASCO26 on X @SitemanCenter and on Bluesky @sitemancenter.bsky.social.

 

Siteman News at #ASCO26

Siteman Cancer Center Shares the Latest in Medical Oncology, Screening Innovation and Translational Science at ASCO

WashU Medicine physician-scientists and others affiliated with Siteman Cancer Center will share findings from multi-institutional studies they lead and will present on health equity, mentorship and more.

Bladder Cancer

WashU Medicine medical oncologist Melissa A. Reimers, MD, of Siteman Cancer Center, discussed the high response rates of the phase 2 SAKK 06/19 trial (NCT04630730); highlighted the emerging role of intravesical BCG (Bacillus Calmette-Guérin), a highly effective immunotherapy, in muscle-invasive bladder cancer; questioned perioperative platinum necessity; and stressed defining complete response to evaluate future bladder-sparing, chemoimmunotherapy-based strategies.

Breast Cancer

WashU Medicine medical oncologist Emily L. Podany, MD, of Siteman Cancer Center, presented on the impact of food access and poverty on somatic genomic profiles and clinical outcomes in metastatic breast cancer.

Endometrial Cancer

Model-based predictions from the pivotal phase 3 ENGOT-ENG-NSGO/GOG-3031/RUBY trial (NCT03981796) suggest the potential for cure with dostarlimab-gxly (Jemperli) plus carboplatin and paclitaxel in patients with mismatch repair–deficient (dMMR)/microsatellite instability–high (MSI-H) primary advanced or recurrent endometrial cancer. WashU Medicine gynecologic oncologist Matthew Powell, MD, of Siteman Cancer Center, will present the full data on May 29.

Hematologic Oncology

WashU Medicine medical oncologist Brad Kahl, MD, of Siteman Cancer Center, shares his thoughts on the science being presented at this year’s conference.

Lung Cancer

Ramaswamy Govindan, MD, FASCO, the Anheuser Busch Endowed Chair in Medical Oncology and associate chief of oncology at WashU Medicine and Siteman Cancer Center, presented the final overall survival results from the randomized phase III Alliance A081105 trial, which evaluated adjuvant erlotinib versus observation after complete resection of EGFR-mutant non-small cell lung cancer.

A new lung cancer screening metric centering on tobacco smoking duration, rather than the current tobacco-pack years measure, decreases potentially missed cancers from 13.3% to 3.9%, while expanding the eligible screening population by 28.8%, according to Brendan Heiden, MD, MS, MBA.

Neuroendicrine Tumors

Cabozantinib provided significant improvements in progression-free survival versus placebo in patients with previously treated advanced neuroendocrine tumors regardless of functional status, according to results from a subgroup analysis of the phase 3 CABINET pivotal trial presented by WashU Medicine medical oncologist Nikolaos A. Trikalinos, MD, of Siteman Cancer Center.

Building Resilient Multidisciplinary Oncology Teams

WashU Medicine head and neck surgeon John Schneider, MD, MA, FACS, of The Brain Tumor Center at Siteman Cancer Center, and others have debuted a model to help organizations establish and sustain high-functioning multidisciplinary oncology care teams. Schneider will present an education session, “Leadership Rx: Prescriptions for Effective Teams,” at ASCO on May 30.

Refer now

Have a patient you need to refer for treatment? Give us a call or fill out our web form.

314-343-0619 Referral form